NASD · Healthcare · Biotechnology · China
Adlai Nortye Group Ltd ADR is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Intrinsic value, DCF valuation, financial health and value investing analysis for the Adlai Nortye Group Ltd ADR stock.
Not valued: We cannot value this company yet.
We do not publish a value for this company: its filings cover two fiscal years and projecting growth needs four in a row.
134 more in this industry show a wider margin of safety.
We do not publish a verdict on ANL yet. A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover two fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.
We do not publish one (as of the 2026-10-30 close). A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover two fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.